Recent Advances in Systemic Therapy. When HER2 is Not the Target: Advances in the Treatment of HER2-negative Metastatic Breast Cancer

Overview

Journal Breast Cancer Res

Specialty Oncology

Date 2009 Sep 12

PMID 19744307

Citations 7

Authors

David W Miles

Affiliations

Soon will be listed here.

Abstract

The anti-human epidermal growth factor receptor 2 (HER2) agent trastuzumab has improved outcomes in breast cancer patients with HER2 over-expressing tumours. However, systemic treatment for patients with HER2-negative disease is still limited to endocrine and cytotoxic therapies. The increasing use of the anthracyclines and taxanes in early stage disease has reduced the available therapeutic options for patients with relapsed disease, and choices are further limited for patients with triple-negative tumours, who typically have a poor prognosis. The novel agents bevacizumab and ixabepilone were recently approved for metastatic breast cancer, and numerous other agents are currently in clinical development that may contribute further valuable therapeutic options.

Citing Articles

Navigating the Blood-Brain Barrier: Challenges and Therapeutic Strategies in Breast Cancer Brain Metastases.

Terceiro L, Ikeogu N, Lima M, Edechi C, Nickel B, Fischer G Int J Mol Sci. 2023; 24(15).

PMID: 37569410 PMC: 10418424. DOI: 10.3390/ijms241512034.

SR-B1-targeted nanodelivery of anti-cancer agents: a promising new approach to treat triple-negative breast cancer.

Johnson R, Sabnis N, Sun X, Ahluwalia R, Lacko A Breast Cancer (Dove Med Press). 2017; 9:383-392.

PMID: 28670138 PMC: 5479299. DOI: 10.2147/BCTT.S131038.

Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches.

Pan Q, Li Q, Liu S, Ning N, Zhang X, Xu Y Stem Cells. 2015; 33(7):2085-92.

PMID: 25873269 PMC: 4478204. DOI: 10.1002/stem.2039.

Tumor-Specific Systemic Treatment in Advanced Breast Cancer - How Long does it Make Sense?.

Wuerstlein R, Bauerfeind I Breast Care (Basel). 2011; 6(1):35-41.

PMID: 21547024 PMC: 3083269. DOI: 10.1159/000324455.

Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer.

Onishi H, Morisaki T, Nakafusa Y, Nakashima Y, Yokohata K, Katano M Int J Clin Oncol. 2011; 16(6):718-21.

PMID: 21327450 DOI: 10.1007/s10147-011-0195-5.

References

Gluz O, Nitz U, Harbeck N, Ting E, Kates R, Herr A . Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann Oncol. 2008; 19(5):861-70. DOI: 10.1093/annonc/mdm551. View

Calabrese C, Almassy R, Barton S, Batey M, Calvert A, Canan-Koch S . Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst. 2004; 96(1):56-67. DOI: 10.1093/jnci/djh005. View

Buzdar A . Clinical experience with epothilones in patients with breast cancer. Clin Breast Cancer. 2008; 8 Suppl 2:S71-8. DOI: 10.3816/cbc.2008.s.003. View

Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Goodwin P . Second consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2006; 18(2):215-25. DOI: 10.1093/annonc/mdl155. View

Martinez N, Sanchez-Beato M, Carnero A, Moneo V, Tercero J, Fernandez I . Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients. Mol Cancer Ther. 2005; 4(5):814-23. DOI: 10.1158/1535-7163.MCT-04-0316. View

Boer K, Lang I, Llombart-Cussac A, Andreasson I, Vivanco G, Sanders N . Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study. Invest New Drugs. 2010; 30(2):681-7. DOI: 10.1007/s10637-010-9538-8. View

Osborne C, Pippen J, Jones S, Parker L, Ellis M, Come S . Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002; 20(16):3386-95. DOI: 10.1200/JCO.2002.10.058. View

Okubo S, Kurebayashi J, Otsuki T, Yamamoto Y, Tanaka K, Sonoo H . Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells. Br J Cancer. 2004; 90(1):236-44. PMC: 2395342. DOI: 10.1038/sj.bjc.6601504. View

James C, Quinn J, Mullan P, Johnston P, Harkin D . BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist. 2007; 12(2):142-50. DOI: 10.1634/theoncologist.12-2-142. View

10.

Rakha E, Tan D, Foulkes W, Ellis I, Tutt A, Nielsen T . Are triple-negative tumours and basal-like breast cancer synonymous?. Breast Cancer Res. 2008; 9(6):404. PMC: 2246182. DOI: 10.1186/bcr1827. View

11.

Johnston S, Hickish T, Ellis P, Houston S, Kelland L, Dowsett M . Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol. 2003; 21(13):2492-9. DOI: 10.1200/JCO.2003.10.064. View

12.

Hilger R, Scheulen M, Strumberg D . The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie. 2003; 25(6):511-8. DOI: 10.1159/000068621. View

13.

Farmer H, McCabe N, Lord C, Tutt A, Johnson D, Richardson T . Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434(7035):917-21. DOI: 10.1038/nature03445. View

14.

Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G . Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol. 2008; 19(11):1847-52. DOI: 10.1093/annonc/mdn395. View

15.

Vanden Bempt I, Van Loo P, Drijkoningen M, Neven P, Smeets A, Christiaens M . Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol. 2008; 26(30):4869-74. DOI: 10.1200/JCO.2007.13.4296. View

16.

Dieras V, Limentani S, Romieu G, Tubiana-Hulin M, Lortholary A, Kaufman P . Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Ann Oncol. 2008; 19(7):1255-1260. DOI: 10.1093/annonc/mdn060. View

17.

Gradishar W, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P . Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005; 23(31):7794-803. DOI: 10.1200/JCO.2005.04.937. View

18.

Nicholson R, Hutcheson I, Harper M, Knowlden J, Barrow D, McClelland R . Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. Ann N Y Acad Sci. 2002; 963:104-15. DOI: 10.1111/j.1749-6632.2002.tb04101.x. View

19.

Chan S, Scheulen M, Johnston S, Mross K, Cardoso F, Dittrich C . Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2005; 23(23):5314-22. DOI: 10.1200/JCO.2005.66.130. View

20.

Nguewa P, Fuertes M, Cepeda V, Alonso C, Quevedo C, Soto M . Poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide enhances apoptosis induction by platinum complexes in cisplatin-resistant tumor cells. Med Chem. 2006; 2(1):47-53. DOI: 10.2174/157340606775197697. View